Abstract

A woman with extremely drug-resistant tuberculosis treated with a drug regimen including linezolid and bedaquiline during her last 3 weeks of pregnancy gave birth to a child without abnormalities. No fetal toxicities were noted by 2 years after delivery. This drug combination might be safe during the late third trimester of pregnancy.

Highlights

  • A woman with extremely drug-resistant tuberculosis treated with a drug regimen including linezolid and bedaquiline during her last 3 weeks of pregnancy gave birth to a child without abnormalities

  • In 2014, a total of 480,000 cases of multidrug-resistant tuberculosis (MDR TB) were present worldwide; 9% of these cases were resistant to fluoroquinolones and aminoglycosides (1 of the 3 available injectable secondline drugs), thereby defining them as extensively drug-resistant TB (XDR TB) [1]

  • Bedaquiline efficacy has been demonstrated in MDR TB and is recommended by the World Health Organization for the treatment of MDR TB [4]

Read more

Summary

Introduction

A woman with extremely drug-resistant tuberculosis treated with a drug regimen including linezolid and bedaquiline during her last 3 weeks of pregnancy gave birth to a child without abnormalities. Considering the severity of XDR TB, pregnant women with this form of TB need to be effectively treated before delivery. Linezolid is an effective drug for treating XDR TB, but side effects such as neurotoxicity and hematologic toxicity frequently occur [6].

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.